These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 21761096)

  • 1. Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
    Feinberg B; Gilmore J; Haislip S; Jackson J; Jain G; Balu S; Buchner D
    Support Care Cancer; 2012 Mar; 20(3):615-23. PubMed ID: 21761096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
    Yeh YC; McDonnell A; Klinger E; Fowler B; Matta L; Voit D; Reddy P
    J Oncol Pharm Pract; 2011 Sep; 17(3):179-85. PubMed ID: 20452991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States.
    Schwartzberg L; Morrow G; Balu S; Craver C; Gayle J; Cox D
    Curr Med Res Opin; 2011 Aug; 27(8):1613-22. PubMed ID: 21696263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.
    Hatoum HT; Lin SJ; Buchner D; Cox D
    Support Care Cancer; 2012 May; 20(5):941-9. PubMed ID: 21533811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
    Kusagaya H; Inui N; Karayama M; Fujisawa T; Enomoto N; Kuroishi S; Nakamura Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Yamada T; Shirai T; Hayakawa H; Suda T
    Lung Cancer; 2015 Dec; 90(3):410-6. PubMed ID: 26791800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study.
    Lin SJ; Hatoum HT; Buchner D; Cox D; Balu S
    BMC Health Serv Res; 2012 Jul; 12():215. PubMed ID: 22823909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
    Wenzell CM; Berger MJ; Blazer MA; Crawford BS; Griffith NL; Wesolowski R; Lustberg MB; Phillips GS; Ramaswamy B; Mrozek E; Flynn JM; Shapiro CL; Layman RM
    Support Care Cancer; 2013 Oct; 21(10):2845-51. PubMed ID: 23748485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
    Miura S; Watanabe S; Sato K; Makino M; Kobayashi O; Miyao H; Iwashima A; Okajima M; Tanaka J; Tanaka H; Kagamu H; Yokoyama A; Narita I; Yoshizawa H
    Support Care Cancer; 2013 Sep; 21(9):2575-81. PubMed ID: 23644992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
    Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N;
    Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
    Tan J; Wang S; Liang X; Li CC; Zhang J; Zhao Z; Kong XR; Deng X; Peng L; Yang C
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28941006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
    Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
    Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
    Schwartzberg L; Barbour SY; Morrow GR; Ballinari G; Thorn MD; Cox D
    Support Care Cancer; 2014 Feb; 22(2):469-77. PubMed ID: 24141698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
    Craver C; Gayle J; Balu S; Buchner D
    J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
    Aapro M; Karthaus M; Schwartzberg L; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Hansen V; Rossi G; Rizzi G; Borroni ME; Rugo H
    Support Care Cancer; 2017 Apr; 25(4):1127-1135. PubMed ID: 27885469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
    Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
    Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients.
    Brugnatelli S; Gattoni E; Grasso D; Rossetti F; Perrone T; Danova M
    Tumori; 2011; 97(3):362-6. PubMed ID: 21789017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).
    Nishio S; Aihara S; Shimokawa M; Fujishita A; Taniguchi S; Hachisuga T; Yanazume S; Kobayashi H; Murakami F; Numa F; Kotera K; Okura N; Toki N; Yokoyama M; Ushijima K
    J Gynecol Oncol; 2018 Sep; 29(5):e77. PubMed ID: 30022637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.